CIRCUMSPOROZOITE PROTEINS OF MALARIA PARASITES CONTAIN A SINGLE IMMUNODOMINANT REGION WITH TWO OR MORE IDENTICAL EPITOPES*

By FIDEL ZAVAŁA, ALAN H. COCHRANE, ELIZABETH H. NARDIN, RUTH S. NUSSENZWEIG, AND VICTOR NUSSENZWEIG

From the Departments of Microbiology (Division of Parasitology) and Pathology, New York University Medical Center, New York 10016

Protective immunity against several species of malaria parasites has been obtained by vaccination with x-irradiated sporozoites (reviewed in reference 1). The serum of protected animals reacts with the surface membrane of sporozoites and neutralizes their infectivity, which suggests that the effect of the vaccine is at least in part antibody mediated. The membrane-associated protective antigens of sporozoites of rodent (2, 3), simian (4), and human (5) malaria have recently been identified by means of monoclonal antibodies (mAb). They are stage-specific proteins that are distributed uniformly over the entire surface of the parasite and are shed when cross-linked by antibodies (3).

Evidence that these circumsporozoite (CS) proteins of different malaria species are structurally, antigenically, and functionally related molecules has been presented elsewhere (6). Of particular interest were the observations that Fab fragments of a mAb against the CS protein of Plasmodium berghei inhibited the attachment and interiorization of these sporozoites into target cells (7). These findings raised the intriguing possibility that some of the epitopes recognized by the mAb might either coincide with or be in close proximity to the areas of the CS molecules that are involved in parasite penetration.

To investigate this phenomenon further we compare here the specificities of a series of mAb against CS proteins of parasites of monkey (P. knowlesi) and human (P. vivax and P. falciparum) malaria, including some that neutralized the infectivity of the sporozoites in vivo (4, 5) or in vitro. We present evidence that in every instance the mAb recognize the same unique region of the CS molecule, which contains at least two identical epitopes.

Materials and Methods

Monoclonal Antibodies. The production and characterization of mAb against sporozoites of P. knowlesi, P. falciparum, and P. vivax are described elsewhere (4, 5). The mAb were partially

---

* Supported in part by grant DPE-0453-C-00-200 2-00 from the Agency for International Development, grant AI 17429 from the National Institutes of Health, and grants from the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Medicine and the Rockefeller Foundation.

1 Abbreviations used in this paper: BSA, bovine serum albumin; CS, circumsporozoite; mAb, monoclonal antibody; NP-40, Nonidet P-40; OVA, ovalbumin; PBS, phosphate-buffered saline; SDS, sodium dodecyl sulfate; STI, soybean trypsin inhibitor.

2 Hollingdale, M. R., E. H. Nardin, S. Tharavanij, A. L. Schwartz, and R. S. Nussenzweig. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells as an in vitro assay of protective antibodies. Manuscript submitted for publication.
purified from ascites fluids by ammonium sulfate precipitation followed by chromatography on Sephadex G200.

**Sporozoites.** Sporozoites of *P. vivax* and *P. falciparum* (isolates from Thailand), as well as *P. knowlesi* (H strain), were obtained from mosquito salivary glands 14-17 d after an infective blood meal (8). Sporozoite extracts were prepared by placing a known number of sporozoites in 500 µl of phosphate-buffered saline containing 1% bovine serum albumin (PBS-BSA). Protein inhibitors were added as previously described (2). Nonidet P-40 (NP-40) was then added to a final concentration of 0.5%, and the mixtures were incubated at room temperature for 1 h. After centrifugation at 100,000 g for 1 h, the supernatants were stored at −70°C.

**Antigen-coated Microtiter Plates.** Sporozoites (6 × 10⁴/ml) were suspended in PBS containing protease inhibitors. 50 µl of this suspension was placed in wells of polyvinylchloride flexible microtiter plates (Dynatech Laboratories, Inc., Alexandria, VA). After freezing (−70°C) and thawing the plates six times, they were stored at −70°C. Before using, the wells were washed three times with PBS-BSA and kept in this solution for 1 h at room temperature.

**Competitive Binding Assays Between Monoclonal Antibodies.** Wells of antigen-coated plates were incubated with 30 µl of cold mAb at a concentration of 50 µg/ml in PBS-BSA. After 1 h of incubation, 10 µl of one of the ¹²⁵I-labeled mAb (1-10 ng, 10⁴-10⁶ cpm) was added to the wells, and the incubation proceeded for an additional hour. Preliminary experiments showed that the above concentration of cold mAb was 25-50 times greater than that required to inhibit completely the binding of the hot homologous mAb to the antigen-coated plates. The wells in the plates were then washed three times with PBS-BSA, dried, and counted in a gamma counter. This procedure was repeated for every possible combination of hot vs. cold mAb against a given CS protein. As negative controls, antigen-coated wells were incubated either with an unrelated mAb or with PBS-BSA before the addition of the labeled mAb. The number of specific counts bound to antigen in the absence of inhibitor mAb was calculated as the difference between the number of counts bound to the wells incubated with the labeled mAb in the presence of PBS-BSA and the number of counts that could not be inhibited by an excess of the homologous, cold mAb, the latter representing nonspecific binding. From these values the percent inhibition of specific binding was calculated for each cold mAb. Results represent the means of duplicates.

**Competitive Binding Assays Between mAb and Anti-Sporozoite Immune Sera.** Immune serum anti-*P. knowlesi* sporozoites from rhesus monkeys was obtained by repeated immunizations with irradiated sporozoites administered intravenously (9). Human immune sera anti-*P. vivax* and anti-*P. falciparum* were obtained from volunteers exposed to multiple bites of irradiated, infected mosquitoes and shown to be protected against sporozoite challenge (10, 11). The anti-*P. knowlesi* immune sera were absorbed with salivary glands of uninfected mosquitoes. 100 µl of immune serum diluted 1:10 in PBS-BSA was incubated with 100 packed salivary glands. After 2 h incubation at room temperature, the sample was centrifuged (8,000 g, 5 min) and the supernatant was used in the assay.

Anti-sporozoite antibodies were detected by incubating dilutions of the immune sera in wells of microtiter plates coated with homologous antigen. After 2 h incubation at room temperature, the wells were washed with PBS-BSA. Then an excess of affinity-purified, ¹²⁵I-labeled IgG of rabbit anti-monkey or rabbit anti-human immunoglobulin (Ig) was added to detect the presence of Ig bound to the immobilized antigen.

The competitive binding assay between mAb and the immune sera was performed as above, except that before the addition of the immune sera, the antigen-coated plates were incubated for 1 h with 30 µl of 10-times-diluted mouse ascites fluids containing mAb. Every experiment included titrations of (a) immune sera after incubation of the plates with mAb against homologous CS proteins, (b) immune sera after incubation with unrelated mAb, and (c) normal monkey or human sera after incubation with an unrelated mAb. The counts obtained in group c represent background and were subtracted from those obtained in groups a and b.

**Sucrose Gradient Ultracentrifugation.** 50 µl of extract obtained from 2.5 × 10⁶ parasites was incubated with 50 µl of a solution containing 2% sodium dodecyl sulfate (SDS) and 6 M urea.
After 1 h incubation at room temperature, 10 μg of molecular weight markers was added (mouse IgG, BSA, ovalbumin [OVA], and soybean trypsin inhibitor [STI]). The mixture (0.2 ml) was placed on the top of a 5-ml tube containing a linear 5–20% sucrose gradient in PBS. The runs were performed in a Beckman L8-80 ultracentrifuge (Beckman Instruments, Inc., Fullerton, CA) with a SW-50.1 rotor (DuPont Instruments–Sorvall Biomedical Div., DuPont Co., Wilmington, DE) at 48,000 rpm for 15 h. Fractions of ~125 μl were collected by perforating the bottom of the tube. Aliquots of each fraction were subject to SDS-polyacrylamide gel electrophoresis. The gels were dried and stained to determine the position of the markers. Each fraction was tested for the presence of antigen by the two assays described below. One of these (the inhibition assay) detects antigen molecules bearing single epitopes and the other (the two-site assay) detects only multivalent antigens.

Inhibition Assay to Detect the Presence of Antigen in Fractions of Sucrose Gradient. 10 μl (5 × 10^4 cpm, 1–5 ng) of radiolabeled mAb (2G3 anti-CS protein of P. knowlesi or 2F2 anti-CS protein of P. vivax) was incubated with 30 μl of each fraction from the sucrose gradient. After 1 h at room temperature, 30 μl of each mixture was added to an antigen-coated plate, incubated for 1 h, washed, and counted. The results were expressed as the number of sporozoites present in each fraction as calculated from a standard curve obtained simultaneously with each assay.

Two-Site/One-Antibody Immunoradiometric Assay. Wells of a microtiter plate were incubated overnight at 4°C with 50 μl of a 10 μg/ml solution of purified mAb in PBS. The wells were washed and incubated for 60 min with PBS-BSA. 35 μl of dilutions of sporozoite extracts was added to separate wells and the plates were incubated at room temperature for 4 h. The wells were washed with PBS-BSA and 30 μl (1 × 10^5 cpm, 5–10 ng) of 125I-labeled mAb (the same used to coat the wells) was added to each well. After 1 h of incubation at room temperature, the wells were washed, dried, and counted. The number of counts bound to control wells that had been coated with an unrelated mAb or with PBS-BSA before addition of extracts was negligible.

When fractions of the sucrose gradient were tested for the presence of antigen, 35 μl of each fraction was added to the antibody-coated wells. The assay proceeded in the same way as described above. The results were expressed as the number of sporozoites contained in each fraction, as calculated from a standard curve obtained on the same day of the experiment.

Radiolabeling of mAb. 25 μl (25 μg) of purified mAb was radiolabeled with 1–2 mCi of 125I, using Iodogen (Pierce Chemical Co., Rockford, IL) and the method suggested by the manufacturers. The free 125I was removed by passage of the sample through Sephadex G-25 PD-10 columns (Pharmacia Fine Chemicals, Piscataway, NJ), followed by extensive dialysis against PBS. Specific activities of the radiolabeled mAb ranged between 2 and 3 × 10^7 cpm per microgram of protein.

Results

Topological Analysis of Antigenic Determinants on CS Proteins. Panels of mAb were used to study the arrangement of the epitopes of CS proteins within single molecules by using a competition binding assay (12–14). These were performed with five mAb to P. vivax derived from three different fusions, five mAb to P. falciparum from two fusions, and six mAb to P. knowlesi from a single fusion. Results are expressed as percentage inhibition of binding of each mAb by the others and calculated as described in Materials and Methods. As seen in Table I, all mAb to P. vivax, P. falciparum, and P. knowlesi inhibited the binding of each other to the homologous CS antigen. This inhibition was specific, because unrelated mAb had no activity. In some cases there was incomplete inhibition. For example, the binding of 125I-2F2 anti-P. vivax was only partially inhibited in the presence of an excess of the other antibodies. However, an excess of cold 2F2 in the incubation medium inhibited 100% of the binding of all radiolabeled antibodies. Similarly, an excess of 8E11 inhibited only 60–80% of the
Table I

| Cold inhibitor (mAb) | Percent inhibition of binding to antigen of the radiolabeled mAb |
|---------------------|---------------------------------------------------------------|
|                     | P. vivax 3D10 5D9 3C1 4E8 2F2                                 |
| 3D10                | 100 102 99 101 59                                            |
| 5D9                 | 83 100 98 101 65                                             |
| 3C1                 | 113 103 100 102 67                                           |
| 4E8                 | 105 100 99 100 60                                            |
| 2F2                 | 100 101 100 116 100                                          |
| Control mAb         | 8 -6 -11 3 6                                                |
| PBS-BSA             | 0 0 0 0 0                                                  |
|                     | P. knowlesi 5H8 2G3 8B8 8A8 8E11 6B8                         |
| 5H8                 | 100 99 101 115 105 121                                      |
| 2G3                 | 96 100 87 78 106 103                                        |
| 8B8                 | 95 94 100 106 107 125                                       |
| 8A8                 | 86 83 94 100 105 128                                        |
| 8E11                | 65 59 86 70 100 105                                         |
| 6B8                 | 88 85 91 95 104 100                                         |
| Control mAb         | 6 0.4 0.5 8 0 0                                               |
| PBS-BSA             | 0 0 0 0 0 0                                                 |
|                     | P. falciparum 3D6 2E7 1E9 2C11 2A10                           |
| 3D6                 | 100 98 99 95 75                                              |
| 2E7                 | 98 100 102 99 50                                              |
| 1E9                 | 100 103 100 100 99                                            |
| 2C11                | 104 100 99 100 100                                           |
| 2A10                | 110 102 106 100 100                                          |
| Control mAb         | 2 0 -4 8 0                                                   |
| PBS-BSA             | 0 0 0 0 0                                                   |

binding of several antibodies to *P. knowlesi*, but all antibodies inhibited 100% of the binding of radiolabeled 8E11 to the antigen. Identical results were obtained when four anti-*P. berghei* mAb were subjected to this analysis (not shown).

**Competitive Assay Between mAb and Anti-Sporozoite Immune Sera.** The experiments described below were performed to determine whether polyclonal human antibodies to sporozoites of *P. falciparum* and *P. vivax*, and monkey antibodies to *P. knowlesi* recognize the same region of the CS molecule as that seen by the homologous mAb. The immune sera were obtained from humans or monkeys vaccinated with irradiated sporozoites and shown to be fully protected when challenged with viable parasites. Wells of plates coated with crude extracts of sporozoites were first incubated with ascites fluids containing mAb to CS proteins. Then immune sera at different dilutions were added to the wells. The presence of polyclonal antibody bound to the immobilized antigen was demonstrated by the specific binding of 125I-labeled, affinity-purified rabbit anti-monkey or rabbit anti-human Ig. As shown in Fig. 1, all polyclonal antisera contained antibodies that bound to the solid-phase-associated antigen, and in each case a single mAb inhibited 70-95% of the binding of the polyclonal antibodies to the wells. It appears, therefore, that in the vaccinated and protected hosts, most
circulating antibodies are directed against CS proteins, and that the mAb and most of the polyclonal antibodies recognize the same epitope.

**Demonstration That the CS Proteins Contain Two or More Identical Epitopes.** This was shown using a two-site immunoradiometric assay. In this type of assay the concentration of antigen is usually measured by means of two antibodies of different specificities. The first antibody, bound to a solid support, serves to isolate and concentrate the antigen. The concentration of bound antigen is then obtained by adding an excess of a second labeled antibody directed against the same antigen but recognizing a different epitope. In the experiments shown in Fig. 2 we performed two-site assays to detect and measure CS proteins in extracts of parasites, but we used a single mAb both in the solid phase and as a radiolabeled developing reagent. We reasoned that use of a single mAb would be equally effective if the antigen contained two identical and topographically separated epitopes. We performed antigen titrations with this two-site/one-antibody assay using extracts of several species of sporozoites. The results
showed that this assay not only detected the antigen specifically, but also that its sensitivity was identical to that of the two-site/two-antibody assay described elsewhere (15); that is, positive results were obtained when extracts contained between $5 \times 10^3$ and $10^4$ sporozoites/ml. Identical results to those of Fig. 2 were obtained when the diluent used in the two-site/one-antibody assay contained 0.5% NP-40.

To determine the molecular weights of the CS proteins that contain the repeated epitopes, solubilized sporozoites were obtained as described in Materials and Methods and then mixed with equal volumes of 2% SDS and 6 M urea. The mixture was overlaid onto a preformed sucrose gradient and subjected to ultracentrifugation. The presence of CS proteins in gradient fractions was determined by means of two different assays; that is, by the two-site/one-antibody immunoradiometric assay, which depends on the multivalency of the antigen, and by the inhibition of binding of radiolabeled antibody to antigen-coated plates, which can detect monovalent antigens. To facilitate comparison of the results of the two assays, the amounts of antigen detected were expressed in sporozoite equivalents, as calculated from standard curves performed on the same day as the experiment.

As seen in Figs. 3A and 4A, the CS protein of *P. vivax* and *P. knowlesi* was detected with the two-site assay in a single peak between BSA and OVA. This position is the expected one for monomers of the CS proteins (and their intracellular precursors).
Extracts of *P. vivax* in 3 M urea and 1% SDS were subjected to ultracentrifugation in linear 5-20% sucrose gradients. Fractions from the gradient were analyzed by two assays. (A) The two-site/one-antibody immunoradiometric assays detect bivalent or polyvalent antigens. These assays were performed with different mAb (2F2, Δ; 5D9, ○; 3C1, □) with identical results. (B) The inhibitory activity of fluid-phase antigen on the binding of a radiolabeled mAb (2F2) to solid-phase-associated antigen was measured. This assay can detect monovalent antigen. Both assays detected antigen sedimenting as a single peak between the OVA and BSA markers.

Extracts of *P. knowlesi* were analyzed exactly as described in the legend of Fig. 3. Assays were performed with 2G3 (Δ), 5H8 (○), and 8E11 (□). The CS protein sedimented as a single peak between the OVA and BSA markers.

that have molecular weights between 40,000 and 60,000 (6). We calculated that the antigen recovered in this peak represented >90% of the amount loaded onto the gradient. Similar results were obtained when the fractions were tested by the inhibition
assay (Figs. 3 B and 4 B).

Identical results were obtained when CS proteins from P. falciparum were subjected to this analysis (not shown). It should be pointed out that two-site/one-antibody immunoradiometric assays of gradient fractions were performed simultaneously with several individual mAb. As also shown in Figs. 3 A and 4 A, the antigenic profiles obtained with all homologous mAb were superimposable. These findings strongly suggest that each monomer is multivalent with respect to epitope expression.

Discussion

The purpose of the experiments described in this paper was to study the number of independent antigenic sites of CS proteins. Our initial approach was to use a competitive binding assay to determine the number of nonoverlapping sites recognized by a panel of mAb. The underlying principle of this assay is that the binding of a radiolabeled antibody to an antigen will be prevented only by other antibodies that recognize the same, or topographically related, sites. Of course, this assumption will be considerably strengthened if the inhibitory effects of the ligands are reciprocal (12-14). As shown in Table I, all mAb to CS proteins of P. falciparum, P. vivax, and P. knowlesi interacted competitively with the respective antigens. The inhibitory effects were quite strong, ranging from 60 to 100%. In a few instances the competition was asymmetrical. This is probably a reflection of the difference in avidity between the antibodies, because in these reactions, the ligand with higher avidity will be favored. Similar effects have been previously described in other systems (12).

The simplest interpretation of these results is that all mAb to CS proteins recognize a single region of the protein, which is immunodominant. This hypothesis is supported by the experiments shown in Fig. 1, which demonstrate that single mAb to the CS protein of P. vivax, P. falciparum, or P. knowlesi inhibited 70-95% of the binding of polyclonal antibodies to the respective antigens. It should be pointed out that the polyclonal antisera had been prepared by vaccination of humans and monkeys with irradiated intact sporozoites and that the assays were performed with crude extracts of sporozoites as a source of antigen. Therefore, it appears that not only are the CS proteins the most immunogenic constituents of sporozoites, but also that the epitope recognized by the immune system of monkeys and humans is identical to that recognized by the mAb.

The detection in CS proteins, whose molecular weights vary between 40,000 and 60,000, of a single immunoreactive area, was unexpected. For example, molecules as small as myoglobin (16,900 mol wt) have five different immunoreactive areas and bind four antibody molecules simultaneously (16). Also, using the competitive binding assay, two epitopes have been found on both envelope proteins of leukemia virus (70,000 and 15,000 mol wt) (12).

The explanation for the high immunogenicity of a single region of the CS proteins is not known. The finding that these molecules contain recurrent epitopes may be relevant because the multiplicity within CS proteins of possible recognition sites by cells of the immune system could increase their antigenicity. The presence of several identical or similar epitopes within CS proteins was demonstrated by their ability to bind simultaneously two or more molecules of the same mAb (Fig. 2). To exclude the
possibility that the apparent multivalence is artifactual and a consequence of aggregation of the antigen, parasite extracts were treated with SDS-urea and subjected to ultracentrifugation in sucrose gradients. Analysis of gradient fractions by two methods showed that a multivalent antigen sedimented between BSA and OVA, as expected for monomers of CS proteins (Figs. 3 and 4).

Another important observation was that every mAb tested detected a recurrent epitope (Figs. 3 A and 4 A). This finding strongly suggests that all antibodies recognize a unique structure of the molecules present in the immunodominant region. In agreement with these observations, a cDNA clone from the CS protein of *P. knowlesi* has been recently isolated, and the sequence encoded by this clone was expressed in a β-lactamase fusion protein of the plasmid pBR322. The fusion protein was detected by the two-site/one-antibody assay. Preliminary DNA sequencing data indicate that the expressed fragment of CS protein contains multiple repeats of a sequence of amino acids that react with the mAb (17).

Whatever the reason for the unique immunologic properties of CS proteins, the present findings, taken together with previous observations, have implications for the development of a malaria vaccine. In the first place, it is clear that CS protein are potent immunogens. Every mAb produced to date in our laboratory against the surface membrane of sporozoites has been shown to be directed against a CS protein. Also, the sera of volunteers vaccinated with sporozoites of *P. vivax* or *P. falciparum* (this paper and reference 5), or the serum of adults living in endemic areas (18), contain antibodies to CS proteins.

Perhaps of even greater significance is the demonstration that a single recurrent epitope appears to contain most of the immunogenic activity of CS proteins. Because the binding of Fab fragments of mAb to this structure neutralizes the infectivity of sporozoites, it is possible that a small portion of the CS molecule represented in this epitope could be used to produce protective immunity in the host.

**Summary**

We have used panels of monoclonal antibodies to circumsporozoite (CS) proteins of *Plasmodium falciparum*, *P. vivax*, and *P. knowlesi* to determine the number of topographically independent epitopes of these antigens. The results of competition binding assays indicated that single regions of the CS molecules were recognized by the homologous monoclonal antibodies. Competition binding assays were also used to study the specificity of antibodies contained in the sera of humans and monkeys that had developed sterile immunity after immunization with irradiated, intact sporozoites. We found that single monoclonal antibodies inhibited 70–95% of the specific binding of the polyclonal antibodies to crude extracts of sporozoites. It appears, therefore, that CS proteins are among the most immunogenic constituents of sporozoites, and that a single region of these molecules contains most of the immunogenic activity.

An additional finding was that the immunodominant region of CS molecules is multivalent with regard to the expression of a single epitope. This was demonstrated by the ability of monomers of CS proteins to bind simultaneously two or more molecules of the same monoclonal antibody.

We acknowledge the expert technical assistance of Dr. Renaldo Manejias. We also thank Dr.
1956 IMMUNODOMINANT REGION OF CIRCUMSPOROZOITE PROTEINS

R. Gwadz, Dr. S. Tharavanij, and Dr. A. P. Assavanich for supplying sporozoite-infected mosquitoes, and Dr. J. Gysin for monoclonal antibodies to \textit{P. vivax}. We are also grateful to Dr. S. Zolla-Pazner and Dr. N. Godson for critical reading of the manuscript.

Received for publication 17 February 1983.

References

1. Nussenzweig, R. S. 1980. Use of radiation-attenuated sporozoites in the immunoprophylaxis of malaria. \textit{Int. J. Nucl. Med. Biol.} 7:89.
2. Yoshida, N., P. Potocnjak, M. Aikawa, V. Nussenzweig, and R. S. Nussenzweig. 1980. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasites. \textit{Science (Wash. DC).} 207:71.
3. Potocnjak, P., N. Yoshida, R.S. Nussenzweig, and V. Nussenzweig. 1980. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. \textit{J. Exp. Med.} 151:1504.
4. Cochrane, A. H., F. Santoro, V. Nussenzweig, R. W. Gwadz, and R. S. Nussenzweig. 1982. Monoclonal antibodies identify the protective antigens of sporozoites of \textit{Plasmodium knowlesi}. \textit{Proc. Natl. Acad. Sci. USA.} 79:565.
5. Nardin, E. H., V. Nussenzweig, R. S. Nussenzweig, W. E. Collins, K. T. Harinasuta, P. Tapchaisri, and Y. Chomcharn. 1982. Circumsporozoite (CS) proteins of human malaria parasites \textit{Plasmodium falciparum} and \textit{Plasmodium vivax}. \textit{J. Exp. Med.} 156:20.
6. Santoro, F., A. H. Cochrane, V. Nussenzweig, E. H. Nardin, R. S. Nussenzweig, R. W. Gwadz, and A. Ferreira. 1983. Structural similarities between the protective antigens of sporozoites from different species of malaria. \textit{J. Biol. Chem.} 258:3341.
7. Hollingdale, M. R., F. Zavala, R. S. Nussenzweig, and V. Nussenzweig. 1982. Antibodies to the protective antigen of \textit{Plasmodium berghei} sporozoites prevent entry into cultured cells. \textit{J. Immunol.} 128:1929.
8. Vanderberg, J., R. S. Nussenzweig, and H. Most. 1968. Further studies on the \textit{Plasmodium berghei}-\textit{Anoph eles stephensi}-rodent system of mammalian malaria. \textit{J. Parasitol.} 54:1009.
9. Gwadz, R. W., A. H. Cochrane, R. Nussenzweig, and R. S. Nussenzweig. 1979. Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of \textit{P. knowlesi} and characterization of surface antigens of these parasites. \textit{Bull. WHO.} 57(Suppl. 1):165.
10. Clyde, D., H. Most, V. McCarthy, and J. Vanderberg. 1973. Immunization against sporozoite-induced falciparum malaria. \textit{Am. J. Med. Sci.} 266:169.
11. McCarthy, V., and D. Clyde. 1977. \textit{Plasmodium vivax}: correlation of circumsporozoite precipitation (CSP) reaction with sporozoite-induced protective immunity in man. \textit{Exp. Parasitol.} 41:167.
12. Stone, M. R., and R. C. Nowinski. 1980. Topological mapping of murine leukemia virus proteins by competition binding assays with monoclonal antibodies. \textit{Virology.} 100:370.
13. Breshkin, A. M., J. Ahern, and D. O. White. 1981. Antigenic determinants of influenza virus hemagglutinin. VII. Topography of the antigenic regions of influenza virus hemagglutinin determined by competitive radioimmunoassay with monoclonal antibodies. \textit{Virology.} 113:130.
14. Lubeck, M. D., and W. Gerhard. 1981. Topological mapping of antigenic sites on the influenza A/PR/8/34 virus hemagglutinin using monoclonal antibodies. \textit{Virology.} 113:64.
15. Zavala, F., R. W. Gwadz, F. H. Collins, R. S. Nussenzweig, and V. Nussenzweig. 1982. Monoclonal antibodies to circumsporozoite proteins identify the species of malaria parasite in infected mosquitoes. \textit{Nature (Lond.)}. 299:737.
16. Atassi, M. Z. 1977. Immunochemistry of Proteins. Plenum Publishing Corp., New York.
17. Ellis, J., L. S. Ozaki, R. W. Gwadz, A. H. Cochrane, V. Nussenzweig, R. S. Nussenzweig, and G. N. Godson. 1983. Cloning and expression of the Plasmodium knowlesi sporozoite surface antigen in E. coli. Nature (Lond.). 302:536.

18. Nardin, E. H., R. S. Nussenzweig, I. A. McGregor, and J. H. Bryan. 1979. Antibodies to sporozoites: their frequent occurrence in individuals living in an area of hyperendemic malaria. Science (Wash. DC). 206:597.